A new trading day began on Tuesday, with Moleculin Biotech Inc (NASDAQ: MBRX) stock price down -5.10% from the previous day of trading, before settling in for the closing price of $0.57. MBRX’s price has ranged from $0.25 to $3.65 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 26.36%. Meanwhile, its annual earnings per share averaged 79.59%. With a float of $27.64 million, this company’s outstanding shares have now reached $30.21 million.
Moleculin Biotech Inc (MBRX) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Moleculin Biotech Inc is 8.74%, while institutional ownership is 6.67%. The most recent insider transaction that took place on Jun 23 ’25, was worth 100,000. In this transaction Chief Financial Officer of this company bought 270,270 shares at a rate of $0.37, taking the stock ownership to the 287,587 shares. Before that another transaction happened on Jun 23 ’25, when Company’s CEO and President bought 675,675 for $0.37, making the entire transaction worth $250,000. This insider now owns 743,607 shares in total.
Moleculin Biotech Inc (MBRX) Earnings and Forecasts
In its latest quarterly report, released on 9/30/2024, the company reported earnings of -2.85 per share, which was $0.1 lower than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.32 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 79.59% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 43.75% during the next five years compared to 26.36% growth over the previous five years of trading.
Moleculin Biotech Inc (NASDAQ: MBRX) Trading Performance Indicators
Here are Moleculin Biotech Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 1.15.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.59, a number that is poised to hit -0.27 in the next quarter and is forecasted to reach -1.13 in one year’s time.
Technical Analysis of Moleculin Biotech Inc (MBRX)
Looking closely at Moleculin Biotech Inc (NASDAQ: MBRX), its last 5-days average volume was 1.36 million, which is a drop from its year-to-date volume of 4.36 million. As of the previous 9 days, the stock’s Stochastic %D was 14.65%.
During the past 100 days, Moleculin Biotech Inc’s (MBRX) raw stochastic average was set at 33.04%, which indicates a significant increase from 3.55% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.0473 in the past 14 days, which was lower than the 0.0787 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.5721, while its 200-day Moving Average is $1.2296. However, in the short run, Moleculin Biotech Inc’s stock first resistance to watch stands at $0.5701. Second resistance stands at $0.5946. The third major resistance level sits at $0.6074. If the price goes on to break the first support level at $0.5328, it is likely to go to the next support level at $0.5200. Should the price break the second support level, the third support level stands at $0.4955.
Moleculin Biotech Inc (NASDAQ: MBRX) Key Stats
With a market capitalization of 16.52 million, the company has a total of 30,286K Shares Outstanding. Currently, annual sales are 0 K while annual income is -21,760 K. The company’s previous quarter sales were 0 K while its latest quarter income was -7,640 K.
